Violet light-filtering IOLs: visual and non-visual benefits
Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.
Drug delivery vs drops: Controlling postop pain, inflammation in cataract patients
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
Single administration of intracameral bimatoprost implant: IOP lowering, safety
Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.
Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.
AAO 2020: Comparing outcomes of xen gel stents in glaucoma practice
Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.
Novartis: Positive DME data for brolucizumab in KITE trial
Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.
FDA grants fourth ODD for treatment of PDE6B gene mutation-associated retinal diseases
The FDA has granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.
Investigators: Asymptomatic COVID-19 patients may have left viral material on surfaces of ophthalmology exam room
A team of Turkish investigators detected COVID-19 viral material on the environmental surfaces of an ophthalmology examination room despite triage systems to exclude patients with the virus.
Company seeks first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications
Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.
2 Clarke Drive Cranbury, NJ 08512